JP5755741B2 - プロリルヒドロキシラーゼインヒビタとしての４−アミノキナゾリン−２−イル−１−ピラゾール−４−カルボン酸化合物 - Google Patents
プロリルヒドロキシラーゼインヒビタとしての４−アミノキナゾリン−２−イル−１−ピラゾール−４−カルボン酸化合物 Download PDFInfo
- Publication number
- JP5755741B2 JP5755741B2 JP2013524250A JP2013524250A JP5755741B2 JP 5755741 B2 JP5755741 B2 JP 5755741B2 JP 2013524250 A JP2013524250 A JP 2013524250A JP 2013524250 A JP2013524250 A JP 2013524250A JP 5755741 B2 JP5755741 B2 JP 5755741B2
- Authority
- JP
- Japan
- Prior art keywords
- pyrazole
- carboxylic acid
- quinazolin
- amino
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 Cc1cccc(C)c1Oc(cc(c(*C1CCOCC1)nc(-[n]1ncc(C(O)=O)c1)n1)c1c1)c1F Chemical compound Cc1cccc(C)c1Oc(cc(c(*C1CCOCC1)nc(-[n]1ncc(C(O)=O)c1)n1)c1c1)c1F 0.000 description 4
- NMHVPOFQHNITRZ-UHFFFAOYSA-N CC(C)c(cc12)ccc1nc(-[n]1ncc(C(O)=O)c1)nc2N1CCOCC1 Chemical compound CC(C)c(cc12)ccc1nc(-[n]1ncc(C(O)=O)c1)nc2N1CCOCC1 NMHVPOFQHNITRZ-UHFFFAOYSA-N 0.000 description 1
- OPJYBGQSJDNVFS-UHFFFAOYSA-N CC1(C)C=CC=C(C)C1OC(C=C1C(N2CCN(C)CCC2)=NC([n]2ncc(C(O)=O)c2)=NC1(C)C1)=C1F Chemical compound CC1(C)C=CC=C(C)C1OC(C=C1C(N2CCN(C)CCC2)=NC([n]2ncc(C(O)=O)c2)=NC1(C)C1)=C1F OPJYBGQSJDNVFS-UHFFFAOYSA-N 0.000 description 1
- HOHBCSVNZKFZRG-UHFFFAOYSA-N CC1N(c2nc3ccc(C4CCCCC4)cc3c(NC#N)n2)N=CC1C(O)=O Chemical compound CC1N(c2nc3ccc(C4CCCCC4)cc3c(NC#N)n2)N=CC1C(O)=O HOHBCSVNZKFZRG-UHFFFAOYSA-N 0.000 description 1
- ZXFSYWQZTNKUDK-UHFFFAOYSA-N CCCN(CCC)c1c(ccc(Oc2ccccc2)c2)c2nc(-[n]2ncc(C(O)=O)c2)n1 Chemical compound CCCN(CCC)c1c(ccc(Oc2ccccc2)c2)c2nc(-[n]2ncc(C(O)=O)c2)n1 ZXFSYWQZTNKUDK-UHFFFAOYSA-N 0.000 description 1
- MWENPMVJXYMYRO-UHFFFAOYSA-N CCN(C)c(c1c2)nc(-[n]3ncc(C(O)=O)c3)nc1cc(F)c2N1CCCCC1 Chemical compound CCN(C)c(c1c2)nc(-[n]3ncc(C(O)=O)c3)nc1cc(F)c2N1CCCCC1 MWENPMVJXYMYRO-UHFFFAOYSA-N 0.000 description 1
- HLQKTXRLWGVIGD-UHFFFAOYSA-N CCN(C)c1c(cc(cc2)N3CCCCC3)c2nc(-[n]2ncc(C(O)=O)c2)n1 Chemical compound CCN(C)c1c(cc(cc2)N3CCCCC3)c2nc(-[n]2ncc(C(O)=O)c2)n1 HLQKTXRLWGVIGD-UHFFFAOYSA-N 0.000 description 1
- UCTKAPXSUBYROW-UHFFFAOYSA-N CCN(CC)C(c1cc(C(C)C)ccc1N1)=NC1(C)[n]1ncc(C(O)=O)c1 Chemical compound CCN(CC)C(c1cc(C(C)C)ccc1N1)=NC1(C)[n]1ncc(C(O)=O)c1 UCTKAPXSUBYROW-UHFFFAOYSA-N 0.000 description 1
- PSGGKAPQDCRHGR-UHFFFAOYSA-N Cc1cccc(C)c1CNC(C(C1)Cl)=CC(C(N(C)C)=C)=C1/N=C(\N)/[n]1ncc(C(O)=O)c1 Chemical compound Cc1cccc(C)c1CNC(C(C1)Cl)=CC(C(N(C)C)=C)=C1/N=C(\N)/[n]1ncc(C(O)=O)c1 PSGGKAPQDCRHGR-UHFFFAOYSA-N 0.000 description 1
- JHYAXUAKMDJAPJ-UHFFFAOYSA-N Cc1cccc(C)c1CNc1nc(-[n]2ncc(C(O)=O)c2)nc2ccc(C3CCCCC3)cc12 Chemical compound Cc1cccc(C)c1CNc1nc(-[n]2ncc(C(O)=O)c2)nc2ccc(C3CCCCC3)cc12 JHYAXUAKMDJAPJ-UHFFFAOYSA-N 0.000 description 1
- XFUJIDZIIMBAQL-UHFFFAOYSA-N Cc1cccc(C)c1Oc(cc1c(NCC2CC2)nc(-[n]2ncc(C(O)=O)c2)nc1c1)c1F Chemical compound Cc1cccc(C)c1Oc(cc1c(NCC2CC2)nc(-[n]2ncc(C(O)=O)c2)nc1c1)c1F XFUJIDZIIMBAQL-UHFFFAOYSA-N 0.000 description 1
- WUVOQDWOGJHBFN-UHFFFAOYSA-N OC(c1c[n](-c(nc(c2c3)N4CCCC4)nc2cc(Cl)c3OC2CCCCC2)nc1)=O Chemical compound OC(c1c[n](-c(nc(c2c3)N4CCCC4)nc2cc(Cl)c3OC2CCCCC2)nc1)=O WUVOQDWOGJHBFN-UHFFFAOYSA-N 0.000 description 1
- GOCVQBYXSLQHSK-UHFFFAOYSA-N OC(c1c[n](-c(nc(c2c3)N4CCCC4)nc2ccc3N2CCCCC2)nc1)=O Chemical compound OC(c1c[n](-c(nc(c2c3)N4CCCC4)nc2ccc3N2CCCCC2)nc1)=O GOCVQBYXSLQHSK-UHFFFAOYSA-N 0.000 description 1
- ZOLSNRMUAQZBLI-UHFFFAOYSA-N OC(c1c[n](-c(nc(c2c3)N4CCOCC4)nc2ccc3-c2ccccc2)nc1)=O Chemical compound OC(c1c[n](-c(nc(c2c3)N4CCOCC4)nc2ccc3-c2ccccc2)nc1)=O ZOLSNRMUAQZBLI-UHFFFAOYSA-N 0.000 description 1
- MSMJLYVXARAWEA-UHFFFAOYSA-N OC(c1c[n](-c(nc(c2c3)N4CCSCC4)nc2ccc3Oc(cc2)ccc2Cl)nc1)=O Chemical compound OC(c1c[n](-c(nc(c2c3)N4CCSCC4)nc2ccc3Oc(cc2)ccc2Cl)nc1)=O MSMJLYVXARAWEA-UHFFFAOYSA-N 0.000 description 1
- XUEHYMTZQBABBE-UHFFFAOYSA-N OC(c1c[n](-c2nc3cc(Oc4ccccc4)ccc3c(NCC3CC3)n2)nc1)=O Chemical compound OC(c1c[n](-c2nc3cc(Oc4ccccc4)ccc3c(NCC3CC3)n2)nc1)=O XUEHYMTZQBABBE-UHFFFAOYSA-N 0.000 description 1
- CQJFJHFTHGNCPU-UHFFFAOYSA-N OC(c1c[n](C(Nc2ccc(C3CCCCC3)cc22)N=C2NC(CCC=C2)=C2Cl)nc1)=O Chemical compound OC(c1c[n](C(Nc2ccc(C3CCCCC3)cc22)N=C2NC(CCC=C2)=C2Cl)nc1)=O CQJFJHFTHGNCPU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37366410P | 2010-08-13 | 2010-08-13 | |
| US61/373,664 | 2010-08-13 | ||
| PCT/US2011/047626 WO2012021830A1 (en) | 2010-08-13 | 2011-08-12 | 4 - aminoquinazolin- 2 - yl - 1 - pyrrazole - 4 - carboxylic acid compounds as prolyl hydroxylase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013536194A JP2013536194A (ja) | 2013-09-19 |
| JP2013536194A5 JP2013536194A5 (https=) | 2014-09-25 |
| JP5755741B2 true JP5755741B2 (ja) | 2015-07-29 |
Family
ID=44533176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013524250A Expired - Fee Related JP5755741B2 (ja) | 2010-08-13 | 2011-08-12 | プロリルヒドロキシラーゼインヒビタとしての４−アミノキナゾリン−２−イル−１−ピラゾール−４−カルボン酸化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US8796263B2 (https=) |
| EP (1) | EP2603502B1 (https=) |
| JP (1) | JP5755741B2 (https=) |
| CN (1) | CN103068821B (https=) |
| AU (1) | AU2011289230B2 (https=) |
| WO (1) | WO2012021830A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8916574B2 (en) | 2009-09-28 | 2014-12-23 | Qilu Pharmaceutical Co., Ltd. | 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors |
| AU2011289230B2 (en) * | 2010-08-13 | 2014-09-04 | Janssen Pharmaceutica Nv | 4 - aminoquinazolin- 2 - yl - 1 - pyrrazole - 4 - carboxylic acid compounds as prolyl hydroxylase inhibitors |
| US9273034B2 (en) | 2011-10-25 | 2016-03-01 | Janssen Pharmaceutica Nv | Meglumine salt formulations of 1-(5,6-dichloro-1H-benzo[D]imidazol-2-yl)-1H-pyrazole-4-carboxylic acid |
| JP6506390B2 (ja) | 2014-09-02 | 2019-04-24 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． | キノリノン系化合物及びその薬物への使用 |
| CA3006300C (en) * | 2015-11-25 | 2024-02-27 | Convergene Llc | Bicyclic bet bromodomain inhibitors and uses thereof |
| EP4048261A4 (en) * | 2019-10-25 | 2023-11-22 | Merck Sharp & Dohme LLC | N-(HETEROARYL)-QUINAZOLINE-2-AMINE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF |
| WO2021216530A1 (en) | 2020-04-20 | 2021-10-28 | Akebia Therapeutics, Inc. | Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer |
| TW202206065A (zh) * | 2020-04-29 | 2022-02-16 | 美商百愛及生物醫藥公司 | 用以治療老化相關病況之缺氧誘導因子脯胺醯羥化酶抑制劑 |
| CN115943144B (zh) * | 2020-08-14 | 2025-05-13 | 成都海博为药业有限公司 | 一种作为pak4激酶抑制剂的化合物及其制备方法和应用 |
| CN114075175A (zh) * | 2020-08-14 | 2022-02-22 | 成都海博为药业有限公司 | 一种作为pak4激酶抑制剂的化合物及其制备方法和应用 |
| TWI896831B (zh) * | 2020-12-31 | 2025-09-11 | 大陸商成都海博為藥業有限公司 | 一種作為ｐａｋ４激酶抑制劑的化合物及其製備方法和應用 |
| WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
| CN117999069A (zh) | 2021-05-27 | 2024-05-07 | 凯克斯生物制药公司 | 柠檬酸铁的儿科调配物 |
| US20240415878A1 (en) * | 2021-10-13 | 2024-12-19 | Board Of Regents, The University Of Texas System | Compositions and Methods for Modulating Mitochondrial Function |
| US20230183356A1 (en) * | 2021-12-14 | 2023-06-15 | Brown University | HIF-1a MODULATORS AND USES THEREOF |
| WO2026015819A1 (en) * | 2024-07-12 | 2026-01-15 | The General Hospital Corporation | Trdmt1 inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
| US20060276477A1 (en) | 2005-06-06 | 2006-12-07 | Fibrogen, Inc. | Treatment method for anemia |
| JP5202327B2 (ja) | 2005-12-09 | 2013-06-05 | アムジエン・インコーポレーテツド | プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用 |
| AR059733A1 (es) | 2006-03-07 | 2008-04-23 | Smithkline Beecham Corp | Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion |
| JO2934B1 (en) | 2006-06-23 | 2015-09-15 | سميث كلاين بيتشام كوربوريشن | Prolyl hydroxylase inhibitors |
| BRPI0713350B1 (pt) | 2006-06-26 | 2022-04-12 | Akebia Therapeutics Inc | Composto, e, composição |
| DE102006050513A1 (de) * | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substitiuierte Dihydropyrazolone und ihre Verwendung |
| JP5557832B2 (ja) * | 2008-03-18 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | 置換４−ヒドロキシピリジン−５−カルボキサミド |
| CN102171481B (zh) * | 2008-08-22 | 2015-04-08 | 因文图斯工程有限公司 | 运动阻尼装置 |
| EP2396316B1 (en) | 2009-02-10 | 2015-07-01 | Janssen Pharmaceutica, N.V. | Quinazolinones as prolyl hydroxylase inhibitors |
| AU2011289230B2 (en) * | 2010-08-13 | 2014-09-04 | Janssen Pharmaceutica Nv | 4 - aminoquinazolin- 2 - yl - 1 - pyrrazole - 4 - carboxylic acid compounds as prolyl hydroxylase inhibitors |
-
2011
- 2011-08-12 AU AU2011289230A patent/AU2011289230B2/en not_active Ceased
- 2011-08-12 EP EP11749643.0A patent/EP2603502B1/en active Active
- 2011-08-12 JP JP2013524250A patent/JP5755741B2/ja not_active Expired - Fee Related
- 2011-08-12 CN CN201180039665.8A patent/CN103068821B/zh active Active
- 2011-08-12 US US13/816,747 patent/US8796263B2/en active Active
- 2011-08-12 WO PCT/US2011/047626 patent/WO2012021830A1/en not_active Ceased
-
2014
- 2014-06-24 US US14/313,892 patent/US9006251B2/en active Active - Reinstated
-
2015
- 2015-03-26 US US14/670,352 patent/US9573940B2/en active Active
-
2017
- 2017-02-17 US US15/436,596 patent/US10246442B2/en active Active - Reinstated
-
2019
- 2019-04-01 US US16/371,400 patent/US10975062B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20180148435A9 (en) | 2018-05-31 |
| US20150197507A1 (en) | 2015-07-16 |
| US20170320859A1 (en) | 2017-11-09 |
| US10975062B2 (en) | 2021-04-13 |
| CN103068821A (zh) | 2013-04-24 |
| US9573940B2 (en) | 2017-02-21 |
| AU2011289230B2 (en) | 2014-09-04 |
| US20140309215A1 (en) | 2014-10-16 |
| CN103068821B (zh) | 2015-02-25 |
| WO2012021830A1 (en) | 2012-02-16 |
| US20200095234A1 (en) | 2020-03-26 |
| US10246442B2 (en) | 2019-04-02 |
| US20130143871A1 (en) | 2013-06-06 |
| EP2603502B1 (en) | 2014-07-30 |
| US9006251B2 (en) | 2015-04-14 |
| AU2011289230A1 (en) | 2013-02-21 |
| JP2013536194A (ja) | 2013-09-19 |
| EP2603502A1 (en) | 2013-06-19 |
| HK1184451A1 (en) | 2014-01-24 |
| US8796263B2 (en) | 2014-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5755741B2 (ja) | プロリルヒドロキシラーゼインヒビタとしての４−アミノキナゾリン−２−イル−１−ピラゾール−４−カルボン酸化合物 | |
| US11618744B2 (en) | Benzoimidazoles as prolyl hydroxylase inhibitors | |
| JP5643233B2 (ja) | プロリルヒドロキシラーゼ阻害物質としてのキナゾリノン | |
| AU2017221812B2 (en) | Quinazolinones as prolyl hydroxylase inhibitors | |
| HK1184451B (en) | 4 - aminoquinazolin- 2 - yl - 1 - pyrrazole - 4 - carboxylic acid compounds as prolyl hydroxylase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140811 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140811 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150512 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150514 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150527 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5755741 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |